IP Library Granted Patent US 9,732,322
Granted Patent B2
US 9,732,322 · App. 14/965,222 · Granted Aug 15, 2017

Compositions for mesoderm derived ISL1+ multipotent cells (IMPs), epicardial progenitor cells (EPCs) and multipotent C56C cells (C56Cs) and methods of producing and using same

Inventors: Stephen Dalton (Athens, GA); David Reynolds (Kilsyth, AU)
Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
C12N5/0657C12N5/0606C12N5/069C12N5/0656C12N5/0661C12N5/0662C12N5/0692C12N2501/105C12N2501/11C12N2501/115C12N2501/155C12N2501/16C12N2501/165C12N2501/195C12N2501/415C12N2501/727C12N2502/13C12N2506/02C12N2506/45C12N2533/78C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,732,322
App. No.
14/965,222
Granted
Aug 15, 2017
Kind
B2
Abstract

The present invention relates to inter alia, methods for the generation and maintenance of Mesoderm-derived ISL1+ Multipotent Progenitors (IMPs), the production of a number of pluripotent cells including and epicardial pluripotent cells (EPCs) and using these cells to produce endothelial cells, cardiomyocytes, smooth muscle cells, vascular cells and other cells and related methods as otherwise disclosed herein. The invention also relates to compositions comprising a population of cells.

Claims (3)

1. A method of producing a population of human epicardial pluripotent cells (EPCs) from human ISL1+ multipotent progenitor cells (IMPs) comprising providing a population of human IMPs produced from differentiating human pluripotent stem cells; exposing said population of IMPs in a differentiation media to an effective amount of Wnt3a, BMP4 and retinoic acid to produce a population of human EPCs; and optionally, isolating said human EPCs.

2. The method according to claim 1 wherein said IMPs are produced from human embryonic stem cells (hESCs).

3. The method according to claim 1 wherein said IMPs are produced from human induced pluripotent stem cells (hiPSCs).

Continuity (7)
Division 13012862 · Jan 25, 2011
Continuation In Part PCTUS2009004334 · Jul 27, 2009
Provisional Application 61137058 · Jul 25, 2008
Provisional Application 61198861 · Nov 10, 2008
Provisional Application 61215621 · May 7, 2009
Provisional Application 61385641 · Sep 23, 2010
Related Publication 20160186140A1 · Jun 30, 2016